Green Cross Holdings Corporation

A005250

KR7005250006

Pharmaceuticals

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
15,560 ^KRW	-2.14%		+1.90%	-4.83%

May. 03	Green Cross Widens Q1 Loss, Sales Inch Up 2%	MT
Mar. 20	Green Cross Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Feldan Bio Inc. announced that it has received funding from Green Cross Holdings Corporation, Consortium QuÃ©bÃ©cois sur la DÃ©couverte du MÃ©dicament, Centre for Commercialization of Regenerative Medicine

March 07, 2023

Feldan Bio Inc. announced that it has received bridge round of funding on March 8, 2023. The transaction included participation from Green Cross Holdings Corporation, Consortium QuÃ©bÃ©cois sur la DÃ©couverte du MÃ©dicament and Centre for Commercialization of Regenerative Medicine. The company issued convertible notes in the transaction.

Latest news about Green Cross Holdings Corporation

Green Cross Widens Q1 Loss, Sales Inch Up 2%	May. 03	MT
Green Cross Holdings Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Tiantan Biological Unit Registers Blood Disorder Treatment; Shares Jump 4%	23-09-11	MT
Green Cross's Net Income Plunges in Q2	23-08-02	MT
South Korea's FTC Imposes 40.9 Billion Won in Fines on Drug Firms for Bid-Rigging	23-07-21	MT
Feldan Therapeutics announced that it has received $16.5 million in funding from Amgen Ventures, Investissement Québec, Investment Arm, Green Cross Holdings Corporation and other investors	23-06-12	CI
Green Cross Holdings Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Green Cross Swings to Loss in Q1	23-05-02	MT
Feldan Bio Inc. announced that it has received funding from Green Cross Holdings Corporation, Consortium QuÃ©bÃ©cois sur la DÃ©couverte du MÃ©dicament, Centre for Commercialization of Regenerative Medicine	23-03-07	CI
Green Cross' Net Profit Falls 27% in Q3	22-11-01	MT
Green Cross Holdings Corporation completed the acquisition of Highlander Factory, Inc. from New Jersey Innovation Institute Inc.	22-05-15	CI
Green Cross' Net Income Rises 3% in March Quarter	22-05-02	MT
Green Cross Holdings Corporation signed an agreement to acquire Highlander Factory, Inc. from New Jersey Innovation Institute Inc. for $73 million.	22-04-18	CI
MedAdvisor Expands to New Zealand with Green Cross Health Deal	22-02-18	MT
Green Cross Lab Cell Corporation completed the acquisition of Green Cross Cell Corporation from a group of shareholders.	21-10-26	CI
Green Cross Lab Cell Corporation entered into a definitive merger agreement to acquire Green Cross Cell Corporation from a group of shareholders for approximately KRW 510 billion.	21-07-15	CI
Aqua Metals : Start-ups aim to change car battery recycling, clean up world's most polluting industry	21-04-23	RE
FACTBOX-Key facts about used lead-acid battery recycling	21-04-20	RE
Market Chatter: Green Cross Wellbeing to Adapt Liver Drug Laennec for COVID-19 Treatment: Drug Safety Ministry	21-03-01	MT
Artiva Biotherapeutics, Inc. announced that it has received $120.000001 million in funding from a group of investors	21-02-25	CI
Artiva Biotherapeutics, Inc. announced that it expects to receive $120.000001 million in funding	21-02-18	CI
EANS-News : AGRANA: Weekly rapid coronavirus tests for employees prove their worth	20-12-09	DJ
Humanscape, Inc. announced that it has received KRW 13.1 billion in funding from Korea Investment Partners Co. Ltd., Green Cross Holdings Corporation, Nau IB Capital, Investment Arm, Carelabs Co.,Ltd, KB Securities Co., Ltd., Investment Arm	20-11-24	CI
Green Cross : Asia offers more flu shots to head off COVID-19 complications	20-09-14	RE
South Korea approves phase II human trial for Green Cross's coronavirus treatment drug	20-08-19	RE

Chart Green Cross Holdings Corporation

Duration

Period

More charts

Company Profile

Green Cross Holdings Corp is a Korea-based investment holding company principally engaged in the manufacture and distribution of pharmaceuticals. The Companyâs products portfolio consists of prescription drugs, blood derivatives, vaccines, cerebrovascular disease treatment, hunter syndrome drugs, as well as over the counter (OTC) drugs, such as skin disease treatment drugs, allergic cream and others. Its products are used for analgesic, treatment of cerebral thrombosis, hypoalbuminemia, genodermatosis and others, as well as prevention of influenza, prophylaxis of varicella, among others. The Company is also involved in the real estate sales and leasing, as well as construction business.

Sector

Pharmaceuticals

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GREEN CROSS HOLDINGS CORPORATION	-4.83%	523M
NOVO NORDISK A/S	+21.85%	546B
JOHNSON & JOHNSON	-4.77%	359B
MERCK & CO., INC.	+16.97%	323B
ABBVIE INC.	+5.69%	290B
ASTRAZENECA PLC	+13.68%	234B
NOVARTIS AG	+3.65%	198B
ROCHE HOLDING AG	-11.12%	194B
AMGEN INC.	+8.08%	167B
PFIZER, INC.	-3.40%	157B